Novel Immunotherapies for Autoimmune Hepatitis by Shamir Cassim et al.
January 2017 | Volume 5 | Article 81
Review
published: 26 January 2017
doi: 10.3389/fped.2017.00008
Frontiers in Pediatrics | www.frontiersin.org
Edited by: 
André Hörning, 
Universitätsklinikum Erlangen, 
Germany
Reviewed by: 
Helen M. Evans, 
Starship Children’s Hospital, 
New Zealand  
Tudor Lucian Pop, 
Iuliu Hat¸ieganu University of 
Medicine and Pharmacy, Romania
*Correspondence:
Pascal Lapierre  
pascal.lapierre.chum@ 
ssss.gouv.qc.ca
Specialty section: 
This article was submitted to 
Pediatric Gastroenterology, 
Hepatology and Nutrition, 
a section of the journal 
Frontiers in Pediatrics
Received: 19 September 2016
Accepted: 10 January 2017
Published: 26 January 2017
Citation: 
Cassim S, Bilodeau M, Vincent C 
and Lapierre P (2017) Novel 
Immunotherapies for 
Autoimmune Hepatitis. 
Front. Pediatr. 5:8. 
doi: 10.3389/fped.2017.00008
Novel immunotherapies for 
Autoimmune Hepatitis
Shamir Cassim1, Marc Bilodeau1,2, Catherine Vincent2 and Pascal Lapierre1,2*
1 Laboratoire d’hépatologie cellulaire, Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), 
Montréal, QC, Canada, 2 Département de médecine, Université de Montréal, Montréal, QC, Canada
Autoimmune hepatitis (AIH) is a multifactorial autoimmune disease of unknown patho-
genesis, characterized by a loss of immunological tolerance against liver autoantigens 
resulting in the progressive destruction of the hepatic parenchyma. Current treatments 
are based on non-specific immunosuppressive drugs. Although tremendous progress 
has been made using specific biological agents in other inflammatory diseases, progress 
has been slow to come for AIH patients. While current treatments are successful in the 
majority of patients, treatment discontinuation is difficult to achieve, and relapses are fre-
quent. Lifelong immunosuppression is not without risks, especially in the pediatric popu-
lation; 4% of patient with type 1 AIH will eventually develop hepatocellular carcinoma with 
a 2.9% probability after 10 years of treatment. Therefore, future treatments should aim 
to restore tolerance to hepatic autoantigens and induce long-term remission. Promising 
new immunotherapies have been tested in experimental models of AIH including T and 
B cell depletion and regulatory CD4+ T cells infusion. Clinical studies on limited numbers 
of patients have also shown encouraging results using B-cell-depleting (rituximab) and 
anti-TNF-α (infliximab) antibodies. A better understanding of key molecular targets in AIH 
combined with effective site-specific immunotherapies could lead to long-term remission 
without blanket immunosuppression and with minimal deleterious side effects.
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iNTRODUCTiON
Autoimmune hepatitis (AIH) is a disease of unknown etiology and, like most autoimmune diseases, 
is a multifactorial process involving genetic susceptibilities, dysregulation of immune tolerance 
mechanisms, and environmental triggers (1, 2). As in many autoimmune diseases, female subjects 
are more frequently affected (1, 2).
Two types of AIH have been described according to the type of circulating autoantibodies. Type 1 
AIH is characterized by the presence of antismooth muscle antibodies and/or antinuclear antibodies 
(2). Type 2 AIH is defined by the detection of liver–kidney microsomal antibody type 1 (LKM1) 
(3–6) and/or liver-cytosol antibody type 1 (LC1) (7). These latter autoantibodies are directed 
against the cytochrome P450 2D6 (CYP2D6) (8–10) and the formiminotransferase-cyclodeaminase 
(FTCD) (7), respectively. Thirty percent of patients with type 2 AIH are anti-LC1 positive; in 10% 
of cases, anti-LC1 is the only serological marker present (7, 11, 12). Type 2 AIH is more frequent in 
the pediatric population than in the adult population (1, 2). Pediatric patients with type 2 AIH are 
often younger than patients with type 1 (1). However, both types respond equally well to current 
treatments (1, 2).
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Conventional therapy for AIH patients consists of immunosup-
pressive drugs, usually a combination of prednisone/prednisolone 
and azathioprine to induce remission of liver inflammation (1, 2). 
Cyclosporine A has also been used successfully in children with 
AIH to induce and maintain remission (13, 14). Tacrolimus and 
mycophenolate mofetil can also be used but mostly in those with 
poor response or poor tolerance to conventional treatment (1). 
Recently, budesonide has been used successfully in both adults 
and children with AIH (15, 16). Although it results in fewer side 
effects such as weight gain, it is less effective than prednisone in 
inducing remission in children (15).
Most patients treated with current therapies show long-term 
complete response to treatment, but progression toward cir-
rhosis and end-stage liver disease occurs in 10–20% of patients 
and liver transplantation may be necessary (1, 3, 17). No clinical, 
laboratory, or histological features can accurately predict initial 
complete response or long-term remission (1, 18–20). Current 
treatments, although effective, are associated with deleterious 
side effects either specific to each drug or as the result of broad 
immunosuppression (1, 2). Treatment withdrawal is difficult to 
achieve with up to 90% relapse rate (21). Recently, careful patient 
selection based on treatment duration and liver biochemistry 
parameters has been reported to improve relapse rates although 
these remain high (22). AIH patients respond well to treatment; 
however, most patients will remain under lifelong immunosup-
pressive therapy.
Therefore, future immunotherapies should aim to restore 
self-tolerance to hepatic autoantigens, abrogating the need 
for long-term immunosuppression with its associated adverse 
effects. This is especially important for pediatric AIH patients for 
whom lifelong broad immunosuppression will lead to increased 
risk of adverse effects.
iMMUNOTHeRAPieS
Current treatments for AIH are based on non-specific immuno-
suppressive therapies, and although development of new specific 
biological immunotherapies have seen great progress in other 
autoimmune and inflammatory diseases, very little progress 
has been made in the past decades for the treatment of AIH (2). 
New therapies targeting specific immune cell subpopulations 
or cytokines could provide an effective mean of inducing rapid 
and complete remission in patients with AIH and minimize del-
eterious side effects. However, the development of such targeted 
therapies requires an understanding of the immune cell subsets 
and mediators of inflammation involved in the pathogenesis of 
autoimmune liver injury in AIH.
T Lymphocytes
Autoimmune hepatitis is considered a T cell-mediated disease; 
liver biopsies of AIH patients show lymphoplasmacytoid infil-
trates with lobular inflammation and bridging necrosis. Analysis 
of liver inflammatory infiltrates from AIH patients shows that 
most of them are composed of CD4+ T lymphocytes with a Th1 
phenotype (23). The involvement of CD4+ T cells in AIH is con-
sistent with the observation that autoantibodies found in AIH 
are immunoglobulin G (IgG) implying a CD4+ T-cell-dependent 
isotype class switching. In addition, CYP2D6-specific CD4+ 
T cells can be isolated from type 2 AIH patients, the same 
autoantigen targeted by LKM1 autoantibody-producing B cells 
(23). Furthermore, there is an overlap between CYP2D6 peptide 
sequences inducing the T- and B-cell autoimmune responses 
in type 2 AIH, highlighting the link between the T and B cell 
responses in AIH pathogenesis (24).
Although liver inflammatory infiltrates are mainly composed 
of CD4+ T cells, CD8+ T cells are found at the interface between the 
liver lobule and the portal tract and are considered responsible for 
hepatocyte injury (25). The cell-to-cell cytotoxic effect of CD8+ 
T cells can be mediated through either Fas/FasL (26–28), perforin/
granzyme pathway (29), TNF receptors (30), or TRAIL receptors 
(31). Liver injury can also result from a bystander effect induced 
by local IFN-γ and TNF-α secretion from activated T cells (32). 
This non-specific damage can result in autoantigens unmasking, 
normally hidden from the immune system, thus amplifying the 
inflammation and immune-mediated liver damage. The cytotoxic 
activity of CD8+ T cells, resulting in hepatocyte death, is believed 
to be the end result of complex interactions between B and T cells. 
Therefore, targeting T cells using depleting anti-CD3 antibodies 
could suppress the T cell-mediated cytotoxicity against hepato-
cytes and possibly lead to the elimination of autoreactive CD4+ 
and CD8+ T cells in these patients.
A murine model of type 2 AIH has been developed based on 
xenoimmunization with human type 2 autoantigens (CYP2D6 
and FTCD). This model replicates most clinical and laboratory 
characteristics of type 2 AIH, such as elevated serum ALT 
levels, liver inflammatory infiltrate that composed of CD4+, 
CD8+ T and B lymphocytes, a Th1 phenotype of autoimmune 
CD4+ T cell response, elevated immunoglobulin levels, and anti-
LKM1 and anti-LC1 autoantibodies (33–37). In addition, as in 
humans, females are more susceptible to AIH, and development 
of the disease is influenced by MHC and non-MHC genes 
(34, 36).
In this model of type 2 AIH, T cell depletion using low-dose 
anti-CD3 antibodies was performed as a mean to induce remis-
sion (Figure 1) (35). The treatment, which reduces the number 
of circulating T lymphocytes by 50%, led to the disappearance 
of liver inflammatory infiltrates, normalization of serum ami-
notransferase levels, and reduced autoantibodies titers (35). In 
addition, residual liver-infiltrating T lymphocytes were no longer 
responsive to autoantigen stimulation, suggesting that these 
lymphocytes had been tolerized (35). These data suggest that 
partial T cell depletion could lead to the restoration of tolerance 
to hepatic autoantigens. However, more work is needed as only a 
single administration of anti-CD3 was performed, which, while 
leading to temporary remission of active AIH, did not confer 
long-term remission (35).
Anti-CD3 T cell-depleting monoclonal antibodies (OKT3) 
are used in the treatment of severe acute rejection after solid 
organ transplantation. Anti-CD3 treatment has been found 
effective in patients with type 1 diabetes (38). Its successful use 
in this T cell-mediated autoimmune disease and the encouraging 
results obtained in the experimental model of type 2 AIH (35, 
38) warrant further investigation into this type of treatment. 
Depletion of a larger number of T cells or over a longer period of 
FigURe 1 | Putative mechanisms of liver damage and new immunotherapies for autoimmune hepatitis. On the basis of recently published data, we 
propose the following model for liver damage and mode of action of new immunotherapies that have shown effectiveness either in preclinical models or in 
preliminary patients’ reports. Expansion of the regulatory CD4+ T cell population (green), through Treg infusion or low-dose IL-2 treatment, can repress CD4+ (yellow) 
and CD8+ (blue) T cell activation and/or expansion and prevent hepatocyte lysis (33, 66). Anti-CD3 monoclonal antibodies (OKT3) can selectively deplete T cells and 
limit the destruction of hepatocytes (35). Selective B-cell depletion using anti-CD20 antibodies (rituximab) has the ability to prevent antigen presentation by 
autoreactive B cells (pink) to T cells, limiting the expansion of autoreactive T cells hence reducing hepatocyte lysis by these cells (41, 42). TNF-α blockade with 
monoclonal antibodies (infliximab) has been shown to reduce liver damage and induce remission of AIH (44–46).
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time may allow the elimination of autoreactive T cells responsible 
for the autoimmune liver injury, hence restoring T cell tolerance 
to hepatic autoantigens and leading to long-term remission. 
However, side effects will need to be carefully monitored since 
T-cell depletion mediated by anti-CD3 relies on an activated cell 
death mechanism that can lead to the release of cytokines such 
as IFN-γ and TNF-α. This can cause a cytokine release syndrome 
with its associated well-recognized toxicity (39). Further research 
is needed to evaluate if the benefits for patients with AIH out-
weigh the potential serious side effects.
B Lymphocytes
Specific autoantibodies, a hallmark of AIH, are important 
markers for diagnosis, but their role in the pathogenesis of AIH 
remains controversial. In type 2 AIH, contrary to type 1, the liver 
autoantigens targeted by the autoantibodies are known. Theses 
autoantigens, targeted by anti-LKM1 and anti-LC1 autoantibod-
ies, CYP2D6 and FTCD, are intracellular proteins expressed at 
low levels. While being mainly found in hepatocytes, they are not 
organ specific. Therefore, there are no obvious reasons to explain 
why these proteins are specifically targeted in AIH. In addition, 
there is no evidence that these specific autoantibodies directly 
mediate the autoimmune response against hepatocytes. However, 
the autoreactive polyclonal B cells found in every AIH patients 
could provide a population of activated professional antigen-
presenting cells (APC) that could efficiently present self-peptides 
to naive T cells and perpetuate the autoimmune T cell reactivity 
against hepatocytes.
In an experimental model of type 2 AIH, the administration 
of a single dose of B-cell-depleting anti-CD20 antibodies resulted 
in a significant reduction in liver inflammation, ALT levels, and 
pro-inflammatory IP10 chemokine expression (Figure  1) (40). 
However, total IgG levels and autoantibodies were not affected 
by this therapy (40). There were significantly more naïve and 
fewer antigen-experienced CD4+ and CD8+ T cells, and T-cell 
proliferation was significantly reduced following anti-CD20 
treatment. In this model, CD19+ B cells served as efficient APCs 
to CD4+ T cells, and anti-CD20 depletion of B cells led to reduced 
CD4+ T cell proliferation and reduced expression of MHC class 
II and CD80 by CD11b+ APCs and by remaining CD19+ B cells 
(40). Anti-CD20 treatment also led to a profound reduction in T 
follicular helper cells (40).
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In adult and pediatric AIH patients, B-cell-depleting anti-
CD20 antibodies (rituximab) have been used successfully in 
difficult-to-treat patients (41, 42). Complete remission has been 
achieved and maintained using rituximab, alone or in combi-
nation with standard therapy, without serious adverse effects 
(41,  42). Although encouraging, these reports are based on 
limited numbers of patients, and larger scale studies are needed 
to test the effectiveness of this specific immunotherapy in AIH 
patients. While rituximab may not replace the current standard 
therapy, it may prove useful in specific cases or to control disease 
flare-up (41).
Cytokine Neutralization
Monoclonal antibody-mediated neutralization of cytokines has 
rarely been used in the treatment of AIH patients likely in part 
due to its complex pathogenesis and the difficulty in identifying 
a single mediator of liver inflammation to neutralize. TNF-α 
neutralization (infliximab) has been used successfully in several 
inflammatory pathologies including rheumatoid arthritis, psoria-
sis arthritis, ulcerative colitis, and Crohn’s disease (43). Infliximab 
has recently been used for the treatment of difficult-to-treat 
AIH patient as a rescue therapy, including a case of pediatric 
AIH (Figure 1) (44–46). In a series of 11 patients treated with 
anti-TNF-α, because they did not respond to standard treatment, 
were intolerant to azathioprine, or developed severe side effects 
from standard therapy, the authors reported induction of remis-
sion in 60% of cases (44). However, 4 of 11 patients developed 
severe infections, some requiring hospitalization, and infliximab 
treatment had to be stopped (44). Patients with difficult-to-treat 
AIH are generally at a higher risk of infectious complications 
following intense immunosuppressive treatment compared to 
those responding to standard treatment, and the presence of 
liver cirrhosis, as in most of these patients, increases the risk for 
infections (47).
These results suggest that TNF-α may have a significant role in 
the autoimmune liver injury present in some patients. However, 
its use as a rescue treatment must be carefully considered in view 
of the potential serious infectious side effects already reported 
(44). In addition, there have been several recent reports of anti-
TNF-α-induced AIH in patients treated for inflammatory bowel 
disease, rheumatoid arthritis, or psoriasis (48–50). Therefore, 
further research is needed to better identify the role of TNF-α in 
the pathogenesis of AIH. The identification of specific biomark-
ers linked to TNF-α activity in AIH could allow the selection of 
patients who would benefit the most from anti-TNF-α-based 
therapy.
Regulatory T Cells
Tregs are critical to maintain immunological tolerance against 
self: furthermore, Treg deficiency leads to the development 
of autoimmune diseases (51). Low numbers or decreased 
functionality of CD4+ Tregs has been reported in patients with 
AIH (52–57). However, normal frequency and functionality of 
FOXP3+ Tregs have also been reported (58). These contradictory 
reports may stem in part from difficulties to effectively identify 
human Tregs based on the markers such as CD25 and FoxP3 that 
can be transiently expressed by activated effector T cells (59). 
In addition, immunosuppressive treatment can also influence 
Treg levels (58). Treg frequencies in adult AIH patients under 
treatment are significantly reduced compared to both untreated 
AIH patients and healthy subjects (58). Moreover, expression 
levels of CD25 can be associated with disease activity in AIH 
patients (58). Recently, a decrease in frequency and a functional 
impairment of CD39+ Tregs have been described in AIH patients 
(54). CD39+ Tregs show preferential suppression over CD4+ Th17 
immunity, and decreased numbers of these Tregs have also been 
described in patients with multiple sclerosis (60).
In an experimental model of type 2 AIH, CD4+ Tregs have 
been found to influence the outcome of the disease (33). The 
susceptibility of a mice strain (C57BL/6) to AIH was found to 
originate from their inability to expand Tregs following exposure 
to human antigens (33). Resistant mice strain 129S/v developed 
significantly higher numbers of Tregs that prevented the develop-
ment of AIH. However, Tregs of the susceptible strain (C57BL/6) 
were fully functional (33). This suggests that the susceptible mice 
strain did not develop AIH due to a functional impairment of 
Tregs but because of the lack of Tregs. Interestingly, CXCR3+ 
Tregs from mice with AIH could be isolated, expanded ex vivo, 
and maintained their functionality (33). Adoptive transfer of 
these ex vivo expanded CXCR3+ Tregs in mice with AIH effi-
ciently targeted the liver that expressed cognate ligands CXCL9 
and CXCL10. This influx of CXCR3+ regulatory T cells to the liver 
restored peripheral tolerance to liver autoantigens and induced 
remission of AIH (Figure 1) (33).
Based on these observations, infusion of autologous ex vivo-
expanded Tregs could be an effective therapeutic approach for 
the treatment of patients with AIH. This idea has generated great 
enthusiasm as it could lead to long-term tolerance to hepatic 
autoantigens (61). Efforts are currently underway to expand Tregs 
for infusion in type 2 AIH patients, including antigen-specific 
Tregs (62–64). Interestingly, Treg recruitment through the CXCR3 
pathway is functional in AIH patients. Therefore, CXCR3+ Tregs 
could be used to target the inflamed liver, potentiating the effec-
tiveness of autologous Treg infusions (65).
It is also possible to expand CD4+ regulatory T cells in vivo 
using low-dose IL-2 injections (66). IL-2 is a growth factor for 
T cells, but it preferentially expands CD4+ regulatory T cells due 
to their high levels of CD25, the IL-2 high-affinity receptor (66). 
Low-dose IL-2 therapy has been used successfully in patients 
with HCV-induced vasculitis, leading to increased numbers of 
circulating Tregs without adverse effects (67). However, since 
IL-2 can also expand effector T cells, further research is needed to 
understand their impact on the regulator/effector T cell balance 
and on the evolution of the disease in view of the large numbers 
of effector T cells present during an AIH.
LONg-TeRM RiSKS ASSOCiATeD  
wiTH iMMUNOSUPReSSiON
Long-term immunosuppression is associated with an increased 
risk of cancer. This is particularly true in transplant patients in 
whom the total exposure to immunosuppressive agents has been 
shown to increase the risk of developing cancer (68). The type 
of cancers arising in this population depends on the number of 
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factors such as age, presence of chronic infections, lifestyle, and 
the underlying disease. The main types of cancer found in this 
population are non-melanoma skin cancer and non-Hodgkin 
lymphomas.
Liver cell cancer, also called hepatocellular carcinoma (HCC), 
is a known complication of almost all chronic liver disease patients 
especially those with underlying cirrhosis. Indeed, the presence 
of cirrhosis is known to be a major determinant in the risk of 
developing HCC (69, 70). In patients with AIH, HCC occurs in 
approximately 4% of patients with a 10-year risk of 2.9% (2). In 
a long-term follow up of 634 Swedish patients with AIH, 4% of 
cirrhotic patients developed HCC with an incidence rate of 0.3% 
per year (71). In another study consisting of 243 patients with 
AIH, 12% of cirrhotic patients developed HCC with an incidence 
rate of 1.1% per year. Finally, in a series of 322 patients with AIH, 
the risk of developing HCC among cirrhotic patients was 1.9% 
(72, 73). In the last two series, the yearly risk is close to or above 
the AASLD recommended threshold of 1.5% that meets cost-
effectiveness ratio for HCC monitoring (74).
These incidence rates are not as high as those found for 
patients with other types of liver diseases (74). However, it has 
been suggested that the longevity of patients with AIH-associated 
cirrhosis and the chronic need for immune-modifying medica-
tions may increase their risk of HCC (2).
To our knowledge, there is no report of HCC developing in 
AIH patients without underlying cirrhosis. This is surprising 
since a large epidemiological study found that cirrhosis was only 
diagnosed in 22% of patients with HCC who otherwise had evi-
dence of risk factors for chronic liver disease (75). HCC has been 
reported in patients following kidney transplantation in absence 
of cirrhosis and viral hepatitis (71). Furthermore, reports have 
described cases of HCC in patients receiving anti-TNF therapy 
without liver cirrhosis (76, 77). HCC has also been reported in a 
patient with common variable immunodeficiency in the absence 
of cirrhosis (78).
One of the strongest evidence that immunosuppression 
increases the risk of developing HCC comes from the studies of 
large cohorts of HIV/HCV co-infected individuals in whom low 
levels of CD4+ T cells are linked with a risk of HCC (79, 80). 
Altogether one needs to be aware of the risk of HCC in AIH 
cirrhotic patients and the potential implications of immunosup-
pression in modulating this risk.
Most non-hepatic malignancies developing during chronic 
immunosuppression are non-melanoma skin cancers. Although 
rarely life threatening, they can represent a significant manage-
ment challenge and lead to repeated and sometimes mutilating 
surgeries for patients (81). As stated earlier, chronic immunosup-
pression is also associated with an increased risk of developing 
non-Hodgkin lymphomas. Recently, two cases of hepatosplenic 
lymphoma have been described in adolescents treated for AIH 
(82). A case of immunodeficiency-associated lymphoproliferative 
disease has also been described in a patient receiving mycophe-
nolate for the control of AIH (83). It is important to note that 
lymphoproliferative disorders are often associated with Epstein–
Barr infection in immunocompromised individuals (84).
If new immunotherapies, such as infliximab and rituximab, 
are to be considered for the treatment of AIH, they have to show a 
safety profile equivalent or improved compared to current thera-
pies. In a pooled analysis of the risk associated with the treatment 
of inflammatory bowel disease with infliximab, no increase in 
the incidence of infection, mortality, or malignancy was found 
compared to the placebo control group (85). In a study on the risk 
of malignancies in 186 rituximab-treated rheumatoid arthritis 
patients, the use of rituximab did not increase the risk of cancer 
(86). Therefore, the safety profiles of rituximab and infliximab do 
not seem to preclude their preliminary use for the treatment of 
AIH, but studies of their safety profile in AIH patients will need 
to be performed. Use of these immunotherapies could also have 
the added benefit of limiting the lifetime risk of pediatric patients 
to adverse events since they have the potential to restore tolerance 
to hepatic autoantigens and induce long-term remission, thereby 
minimizing the use of immunosuppression in these patients.
CONCLUSiON AND FUTURe 
PeRSPeCTiveS
A better understanding of the pathogenesis of AIH will likely 
reveal new pathways and molecular/cellular targets that could be 
efficiently used for treatment. In addition, better knowledge of 
immunological tolerance and autoimmunity may also open new 
therapeutic avenues. For example, a promising new experimental 
therapy is currently being tested in an animal model of type 2 AIH 
that consists of an antigen-specific intranasal desensitization that 
can lead to the restoration of immunological tolerance to type 
2 AIH autoantigens and remission of liver inflammation (87). 
This type of therapy is of course dependent on our knowledge of 
targeted autoantigens and therefore confined, for the time being 
at least, to the treatment of type 2 AIH. However, this type of 
antigen-specific immunotherapy could do away with blanket 
immunosuppression, as is currently standard care in AIH patients.
The search for a magic bullet for the treatment of AIH will likely 
prove elusive. However, development of specific immunothera-
pies in combination with a better understanding of this complex 
disease, including the identification of specific biomarkers, will 
provide a broader arsenal of treatments tailored for use in selected 
patients. The variable response to treatment by patients with AIH 
is a testament to the complexity and likely heterogeneous nature 
of this disease. A better understanding of key molecular effectors 
in AIH combined with effective site-specific immunotherapies 
will likely be the most efficient way to induce long-term remission 
with minimal deleterious side effects.
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